CAT off on failed Trabio Phase II/III

Cambridge Antibody (LSE:CAT; CATG) was off $1.41 (11%) to $11.34 on NASDAQ on Tuesday after reporting that preliminary results showed its Trabio lerdelimumab (CAT-152) missed the primary endpoint of i...